Tumor Antigen Loaded Autologous Dendritic Cells
Renal Cell Carcinoma
Explore 271 assets in Renal Cell Carcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Inge Marie Svane
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00197860CT.gov Dendritic Cell Based Therapy of Renal Cell Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tumor Antigen Loaded Autologous Dendritic Cells (this asset) | Inge Marie Svane | P1/2 | CCC · 48 |
| Sorafenib | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BBB |
| Pazopanib | Imbioray (Hangzhou) Biomedicine Co., Ltd. | P4 | BBB |
| Belzutifan | Vall d'Hebron Institute of Oncology | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Interferon-Alfa-2A | Central European Society for Anticancer Drug Research | P3 | BB |
| Everolimus | Merck Sharp & Dohme LLC | P4 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P4 | BB |
+42 more in the Renal Cell Carcinoma cohort
Other indications for Tumor Antigen Loaded Autologous Dendritic Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P1/2 | CCC · 51 |
| Hepatocellular Carcinoma | — | P1 | CC · 41 |
| Urinary Bladder Carcinoma | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tumor Antigen Loaded Autologous Dendritic Cells in Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tumor-antigen-loaded-autologous-dendritic-cells-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →